Delamare PLC
Delamare PLC (public limited company) is a Luthori multinational pharmaceutical company headquartered in Fort William, Luthori. It is Terra's second-largest by prescription sales. Delamare is listed as DLM on the Luthori Stock Exchange (LSE) and is a constituent of the Fort William Herald 100 Index (FWH100). As of January 4136, it had a market capitalization of $100 billion.
Delamare develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Delamare's products include Flingenza, used to treat hypertension; Phenyl, for colorectal cancer; and Plastolam, for type 1 and type 2 diabetes mellitus.
Delamare was founded in Labonne, Rildanor in October 4061 by Georges Hugues as Synthélabo before merging with Laboratoires Moret in 4092 to form Delamare S.A. In January 4136, Delamare S.A. relocated its headquarters to Fort William, Luthori and underwent restructuring. Since January 4136, the company has been registered in Luthori as Delamare PLC.
The Delamare Plant located in a suburb outside metropolitan Fort William employs 1,400 workers
Products
Prescription Drugs
Cardiovascular
- Pugidem (atherothrombosis)
- Gumeria (thrombosis)
- Flingenza (hypertension)
Oncology
- Clavoxx (female infertility)
- Nerfolam (prostate cancer)
- Xanprophen (breast, lung, prostate cancer
- Phenyl (colorectal cancer)
Diabetes
- Plastolam (type 1 and type 2 diabetes mellitus)
- Spinenza (type 1 and type 2 diabetes mellitus)
Over-the-counter Drugs
- Mopepia (antacid)
- Welolan (pain and fever)
- Flozellian (allergic rhinitis)
- Ragadrine (aches, pains, headaches)
Vaccines
- Damac (influenza)
- Swazbella (rabies)
- Gravax (tetanus)
- Scanestra (typhoid)
- Plumaxil (yellow fever)
Finances
ITB Balance: 131,711,411.20 LPD
Annual Net Revenues
December 4135: +9,230,648.07 LPD
December 4136: +9,494,644.60 LPD (+2.86%)
December 4137: +9,586,742.65 LPD (+0.97%)
December 4138: +9,735,337.16 LPD (+1.55%)
December 4139: +9,914,467.36 LPD (+1.84%)
December 4140: +10,170,260.61 LPD (+2.58%)
December 4141: +10,398,074.44 LPD (+2.24%)
December 4142: +10,714,175.90 LPD (+3.04%)
December 4143: +10,867,388.61 LPD (+1.43%)
December 4144: +11,013,011.61 LPD (+1.34%)
December 4145: +11,318,072.03 LPD (+2.77%)
December 4146: +11,528,588.16 LPD (+1.86%)
Governance
Chairman of the Board of Directors: Audric Brun
Chief Executive Officer: Baptiste Ferrand
Chief Operating Officer: Gordon Henry
Chief Financial Officer: Janet Butler
General Counsel: Andrew Wood
Executive Vice President on Medical Affairs: Helen Whitworth
Executive Vice President on Research and Development: Russell Chadwick
For more information, visit www.delamare.lu